Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Maves vs Somira Health

Maves
Graded #88

Higher grade

vs+9.599999999999994
Somira Health
Graded #278

Lower grade

The verdict

Maves takes it — 71.8/100 to 62.2/100.

Maves grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Maves, operating under parent company Homera Health, is a performance-framed telehealth platform offering compounded semaglutide and tirzepatide for weight loss plus sermorelin for anti-aging, with…

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMaves +33
84
51
Dose & formulationMaves +1
65
64
Clinical oversightSomira Health +1
76
77
Labs & monitoringSomira Health +10
52
62
FulfillmentMaves +4
87
83
Contract termsMaves +30
55
25
Maves · left barSomira Health · right bar

The numbers

MetricMavesSomira Health
WeighScore71.8/10062.2/100
GradeCC
Scorecard rank#88#278
Semaglutide$99/mo (starting dose, first-month rate, compounded)$190/mo (compounded)
TirzepatideNot disclosed$285/mo (compounded)
CoverageAll 50 statesCoverage not published
Brand-name accessYesCompounded only
Oral / sublingualInjection onlyInjection only
Maves

Graded #88 · C

Strengths

  • LegitScript Certified
  • Publishes the FDA compounded-medication disclaimer
  • $99/mo first-month intro pricing on semaglutide — among the most aggressive we track
  • All 50 states covered, stated explicitly
  • Both brand (Maves) and parent (Homera Health) disclosed for accountability

Where it loses points

  • 503A pharmacy partner not named (only 'licensed U.S. pharmacies')
  • Tirzepatide pricing not stated on the homepage — only listed as an offering
  • Named medical director / clinical leadership not disclosed
  • Refund and cancellation policy not detailed publicly
  • Corporate address and arbitration venue not disclosed
Somira Health

Graded #278 · C

Strengths

  • Transparent flat monthly pricing that does not increase as you titrate (semaglutide $189.99/mo, tirzepatide $284.99/mo)
  • Quarterly plans lower the effective monthly cost (semaglutide $136.66/mo, tirzepatide $221.66/mo)
  • Free overnight shipping, with syringes and alcohol wipes included in every order
  • Simple, fast online intake reviewed by a licensed provider; no insurance required
  • Both weekly compounded GLP-1 options offered: semaglutide and tirzepatide

Where it loses points

  • Compounded medications are not FDA-approved (the site discloses this) — not brand Wegovy, Ozempic, Zepbound, or Mounjaro
  • The compounding pharmacy partner is not named
  • State-availability list is not published
  • No LegitScript certification displayed
  • New, thin platform with limited public detail on the provider network, lab monitoring, or ongoing support

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard